* Please be kindly noted that our services and products can only be used for research to organizations or companies and not intended for any clinical or individuals.
Endoplasmic Reticulum-Associated Degradation (ERAD) is a cellular protein quality control pathway that recognizes aberrant, misfolded, improperly glycosylated, or persistently retained proteins in the endoplasmic reticulum (ER), retrotranslocates selected substrates to the cytosolic side, promotes ubiquitination through ER-resident ubiquitin ligase machinery such as HRD1/SYVN1 and gp78/AMFR, and directs them toward proteasome-mediated degradation. Unlike conventional Proteolysis Targeting Chimeras (PROTACs), which typically recruit an E3 ubiquitin ligase through a dedicated E3 ligand, ERAD-based degradation technology aims to route a protein of interest (POI) into endogenous ER quality control and disposal systems by manipulating glycosylation status, ER localization, membrane anchoring, chaperone engagement, or ERAD substrate processing.
BOC Sciences provides ERAD-based degradation technology development services for pharmaceutical, biotechnology, and research organizations seeking to explore noncanonical targeted protein degradation strategies, especially for secretory pathway proteins, membrane-associated proteins, ER-localized proteins, engineered fusion proteins, antibody-derived binders, and difficult targets that are not readily addressed by classical cytosolic degrader modalities. Our service scope covers ERAD feasibility assessment, Glyco-ERAD design, ER membrane anchoring and ER retention signal engineering, chaperone redirecting molecule design, ERAD flux modulation, substrate ubiquitination analysis, degradation profiling, and iterative mechanism validation. By integrating protein engineering, chemical biology, cellular assay development, and degradation-focused interpretation, we help clients build practical ERAD-based degradation programs with clearer mechanistic direction and more decision-ready data.
Services
BOC Sciences' Comprehensive ERAD-Based Degradation Technology Development Services
Glyco-ERAD Degrader Development
Glyco-ERAD degrader development introduces N-linked glycosylation signals into the POI, enabling the modified protein to enter the calnexin/calreticulin cycle, be recognized by ER degradation-enhancing alpha-mannosidase-like protein (EDEM), and undergo HRD1/gp78-associated ubiquitination. This strategy is suitable for secretory pathway proteins, engineered glycoproteins, ER-accessible domains, and folding-sensitive targets. Molecular formats may include engineered N-X-S/T motifs, glycosylation donor systems, and glycosyltransferase-modulating molecules.
Assessment of POI topology, ER accessibility, and glycosylation feasibility
Comparison of N-X-S/T motif positions to preserve target detection and function
Evaluation of glycan-dependent ERAD recognition, ubiquitination, and degradation
ER Membrane-Anchored and ER-Retention Degrader Development
ER membrane-anchored and ER-retention degrader development forces a target protein to localize at the ER membrane or remain within the ER lumen, increasing exposure to ER quality control and ERAD machinery. Common elements include CAAX boxes, glycosylphosphatidylinositol (GPI) anchors, transmembrane domains, KDEL/HDEL retention motifs, and KKXX retrieval signals. Molecular formats include fusion proteins, nanobody-anchor peptide conjugates, antibody-fragment constructs, and modular ER-localizing binders.
Selection of ER anchoring, retention, or retrieval motifs based on target topology
Fusion protein, nanobody-anchor peptide, and antibody-fragment construct design
Validation of ER localization, retention efficiency, and target degradation
Chaperone-Redirecting ERAD Degrader Development
Chaperone-redirecting ERAD degrader development uses Hsp70, Binding Immunoglobulin Protein (BiP/GRP78), or related chaperones to guide selected targets toward ERAD entry. Unlike PROTACs, this strategy does not directly recruit an E3 ligase; instead, the degrader contains a POI-binding domain and a chaperone-engaging domain, allowing endogenous ERAD machinery to complete recognition, ubiquitination, and degradation. Molecular formats include bifunctional binders, peptide redirectors, nanobody-derived constructs, and small-molecule/binder hybrids.
Design of POI binder-chaperone engager architectures
Optimization of BiP/Hsp70-engaging motifs and domain orientation
Evaluation of target engagement, chaperone association, ERAD routing, and degradation kinetics
Deglycosylation-Inhibition ERAD Flux Degrader Development
Deglycosylation-inhibition ERAD flux degrader development enhances ERAD efficiency by reducing substrate escape during glycoprotein processing. By modulating peptide:N-glycanase-related systems or using PNGase F-inspired assay models, this strategy helps maintain glycosylated substrates within productive ERAD processing routes. Molecular formats mainly include small-molecule modulators or inhibitor tool compounds for regulating deglycosylation, substrate persistence, ubiquitination, and proteasome-dependent clearance.
ERAD flux assessment for glycosylated substrates with incomplete degradation
Small-molecule modulation strategy for deglycosylation-associated substrate escape
Our Solutions for ERAD-Based Degradation Development Challenges
ERAD-based degradation programs can fail when the engineered substrate signal, ER localization route, chaperone interaction, ubiquitination event, and degradation assay are not aligned. BOC Sciences provides integrated solutions that connect molecular design with ERAD biology, helping clients identify why a design works, why it fails, and how it can be improved through a rational optimization cycle.
Solution for Strategy Selection and Target Feasibility
A frequent challenge is choosing the wrong ERAD entry route for the target. For example, a soluble cytosolic protein may not respond to simple ER retention tags, while a membrane-associated target may require topology-aware anchoring. We solve this by mapping POI localization, exposed domains, glycosylation feasibility, folding sensitivity, available binders, and desired readouts. Based on this assessment, we recommend a technically grounded route such as N-linked glycosylation engineering, ER membrane recruitment, KDEL/HDEL retention, KKXX retrieval, or chaperone redirecting.
Solution for Glyco-ERAD Design Optimization
Glyco-ERAD requires more than inserting a glycosylation sequon. The engineered N-X-S/T motif must be accessible, compatible with local structure, and positioned so that the modified POI can enter glycoprotein quality control without destroying the assay signal. We design multiple glycosylation site variants, model local structural impact, compare glycosylation-dependent degradation behavior, and evaluate calnexin/calreticulin cycle engagement, EDEM-associated recognition, and ERAD-linked ubiquitination to identify the most productive design.
Solution for ER Anchoring, Retention, and Chaperone Redirecting
ER recruitment strategies may show weak degradation if the target is retained in the wrong orientation, fails to interact with ERAD sensors, or triggers nonspecific protein accumulation. We address this by comparing CAAX, GPI, transmembrane domain, KDEL/HDEL, and KKXX-based designs, then pairing them with localization imaging, target quantification, and pathway-dependence assays. For chaperone redirecting designs, we optimize target-binding domain orientation and BiP/Hsp70 engagement so that the molecule guides the POI toward ERAD entry without requiring direct E3 ligase recruitment.
Solution for Mechanistic Confirmation and Data Interpretation
ERAD projects require careful interpretation because protein reduction can be caused by translational suppression, secretion blockade, aggregation, altered antibody recognition, or broad ER stress. We design orthogonal validation packages using dose-response and time-course degradation assays, target ubiquitination analysis, proteasome-dependence studies, ER localization confirmation, glycosylation-state tracking, and pathway rescue experiments. This allows clients to identify genuine ERAD-mediated degradation and prioritize designs with stronger mechanistic confidence.
Choose BOC Sciences to Build More Reliable ERAD-Based Degradation Programs!
From Glyco-ERAD engineering and ER retention construct design to chaperone redirecting molecules, ERAD flux modulation, ubiquitination analysis, and degradation profiling, BOC Sciences provides tailored support for noncanonical targeted protein degradation projects. Our interdisciplinary expertise helps clients reduce design uncertainty, generate interpretable ERAD mechanism data, and advance promising degradation strategies with greater confidence.
Our ERAD-Based Degradation Solutions Support Diverse R&D Organizations
Research Institutes and Academic Laboratories
Academic teams often use ERAD-based degradation systems to explore protein quality control, glycoprotein folding, ER stress biology, membrane protein turnover, and degrader modality comparison. We support these projects with flexible construct design, chemical biology, assay development, and mechanistic interpretation modules that help generate reliable research data.
Biotechnology Companies
Biotechnology companies may need fast proof-of-concept data to determine whether ERAD routing can support a new degradation program for a difficult secretory pathway or membrane-associated target. BOC Sciences helps accelerate early decision-making through target feasibility review, design matrix generation, cellular degradation testing, and mechanism-focused troubleshooting.
Pharmaceutical Discovery Teams
Pharmaceutical discovery teams can use ERAD-based degradation to evaluate alternative protein removal strategies for targets that are poorly addressed by conventional occupancy-driven inhibition or classical degrader systems. We provide systematic support for target routing, engineered substrate design, degradation validation, selectivity assessment, and iterative optimization.
CROs / Technical Service Platforms
Contract research organizations and technical platforms may require specialized ERAD expertise to complement internal protein engineering, degrader chemistry, or cell biology capabilities. We offer modular collaboration models covering Glyco-ERAD design, ER retention fusion construction, chaperone redirecting concept development, assay execution, and data interpretation.
End-to-End ERAD-Based Degradation Technology Development Workflow
01
Inquiry and Requirement Collection
Understand the client's POI, localization, available binders, construct information, target biology, desired degradation readouts, preferred cell models, and project-stage objectives.
02
ERAD Feasibility and Strategy Assessment
Evaluate target topology, glycosylation potential, ER access, chaperone compatibility, membrane anchoring feasibility, assay availability, and technical risks.
03
Design Route Selection and Proposal Development
Define whether the project should focus on Glyco-ERAD, ER retention, membrane anchoring, chaperone redirecting, deglycosylation inhibition, or a comparative design matrix.
04
Technical Data Transfer and Project Initiation
Receive target sequences, structural models, binder information, plasmid maps, assay protocols, cell line background, and project-specific design constraints.
05
ERAD Construct or Molecule Design
Generate glycosylation variants, ER retention fusions, membrane anchoring designs, nanobody-anchor conjugates, chaperone redirecting molecules, or small-molecule flux modulators.
06
Expression, Localization, and Early Validation
Evaluate construct expression, ER localization, glycosylation state, chaperone association, and initial target degradation under defined cellular conditions.
07
Mechanistic Degradation Profiling
Measure dose response, time dependence, ubiquitination, proteasome dependence, pathway rescue, ER stress markers, and target-selective degradation behavior.
08
Optimization, Reporting, and Next-Step Recommendation
Deliver experimental data, comparative design interpretation, degradation profiles, and practical recommendations for the next ERAD design or validation cycle.
ERAD-based approaches provide an alternative to E3-ligase-recruiting bifunctional degraders by exploiting endogenous ER quality control, chaperone recognition, glycoprotein processing, and proteasome-linked substrate disposal.
Supports Secretory and Membrane-Associated Targets
Because many secretory pathway and membrane proteins pass through the ER, ERAD-based routing can be valuable for targets that are difficult to address using only cytosolic degrader strategies.
Enables Multiple Molecular Formats
ERAD strategies can be implemented through engineered glycosylation sites, fusion proteins, ER retention motifs, nanobody-anchor peptide conjugates, chaperone redirecting molecules, and small-molecule flux modulators.
Connects Protein Engineering with Degradation Biology
ERAD-based development combines target topology analysis, structural design, glycosylation engineering, ubiquitination validation, and degradation profiling to produce mechanism-aware optimization data.
Applications
Applications Supported by Our ERAD-Based Degradation Platform
Glycoprotein and Secretory Pathway Target Degradation
Design of N-linked glycosylation variants for glycan-dependent ERAD routing
Evaluation of calnexin/calreticulin cycle engagement and EDEM-associated recognition
Degradation assessment for engineered secretory pathway proteins and folding-sensitive constructs
ER membrane anchoring designs using transmembrane domains, CAAX motifs, or GPI anchoring signals
ER retention or retrieval designs using KDEL/HDEL and KKXX signal motifs
Degradation profiling for receptor-like, membrane-associated, or ER-resident proteins
Comparison of ERAD routing with other targeted protein degradation modalities
Chaperone-Assisted Target Redirecting
Development of target binder and BiP/Hsp70-engaging bifunctional molecules
Design of chaperone-interacting peptides, antibody fragments, nanobodies, and modular binders
Mechanistic studies to differentiate chaperone redirecting from direct E3 ligase recruitment
Optimization of target engagement, chaperone recruitment, and ERAD-dependent protein loss
ERAD Flux and Substrate Processing Research
Investigation of deglycosylation inhibition as a method to reduce ERAD substrate escape
Analysis of glycosylated substrate accumulation, ubiquitination, and proteasome-dependent clearance
Evaluation of ERAD pathway bottlenecks involving recognition, retrotranslocation, and substrate processing
Data-driven prioritization of molecular and engineering strategies for stronger degradation outcomes
Case Study
Client Success Stories: ERAD-Based Degradation Technology Development
Project Background
A biotechnology research team wanted to evaluate whether a secretory pathway protein with limited small-molecule ligandability could be degraded through glycosylation-dependent ERAD routing. The target contained a flexible extracellular-like domain and two structurally sensitive regions, making random glycosylation insertion risky. The client needed a design strategy that could introduce ERAD-recognition features while preserving antibody-detectable epitopes for degradation assays.
Our Support
BOC Sciences first mapped solvent-exposed loops and identified six candidate positions for N-linked glycosylation motif insertion. After structural review, three positions were selected for construct generation because they were distant from the client's detection epitope and predicted to tolerate N-X-S/T motif engineering. We then compared nine glycosylation variants across three motif contexts and evaluated expression, glycosylation shift, ER localization, and target degradation over 8 h, 16 h, and 24 h treatment windows. Two variants showed strong ER retention but weak degradation, suggesting accumulation without productive ERAD routing. The best construct displayed a clear glycosylation-dependent mobility shift, increased ubiquitination signal, proteasome-sensitive target reduction, and Dmax above 65% under optimized cellular assay conditions. These results allowed the client to select one Glyco-ERAD construct for downstream mechanism studies and discard designs that only caused nonspecific retention.
Client Testimonial
BOC Sciences helped us convert a broad ERAD concept into a structured engineering campaign. Their design logic made it possible to separate productive Glyco-ERAD routing from simple ER accumulation, which was critical for our decision-making.
Project Background
A drug discovery group was investigating a cytosolic signaling protein that was poorly addressed by conventional degrader designs due to limited E3-compatible geometry. The client had a high-affinity peptide binder and wanted to test whether a chaperone redirecting strategy could route the target toward ERAD machinery without adding a classical E3 ligase ligand. Their main concern was whether target loss could be achieved without losing specificity or triggering broad stress-associated protein reduction.
Our Support
We designed 16 chaperone redirecting candidates containing the client's peptide binder, three BiP/Hsp70-engaging motif variants, and four linker architectures with different spacing and rigidity. Early screening showed that two short-linker formats retained target binding but produced no measurable degradation, indicating poor chaperone-routing geometry. We then prioritized a semi-rigid mid-length linker series and paired degradation testing with target engagement, chaperone association, ubiquitination analysis, and proteasome-dependence evaluation. The optimized candidate achieved reproducible target reduction in two cellular models, with stronger degradation at 16 h than 6 h and reduced nonspecific stress-marker induction compared with the first-round constructs. The client received a defined molecular template and a mechanistic dataset supporting further chaperone redirecting optimization.
Client Testimonial
The BOC Sciences team did more than design molecules. They helped us understand which parts of the chaperone redirecting format controlled degradation, and their assay package gave us confidence that the observed protein loss was pathway-relevant.
Why Us
Why Choose BOC Sciences for Your ERAD-Based Degradation Project?
Integrated ERAD Strategy Development
We provide coordinated support across target feasibility assessment, Glyco-ERAD design, ER retention engineering, chaperone redirecting, flux modulation, degradation assays, and optimization.
Deep Understanding of ER Quality Control Biology
Our team considers calnexin/calreticulin cycling, EDEM recognition, HRD1/gp78-associated ubiquitination, retrotranslocation, deglycosylation, and proteasome-linked degradation when designing ERAD workflows.
Flexible Molecular and Engineering Formats
Clients can access genetic engineering, protein construct design, nanobody-anchor formats, peptide-based redirecting systems, small-molecule modulation concepts, or complete ERAD development packages.
Mechanism-Focused Validation
We design orthogonal validation studies to determine whether target reduction is associated with ERAD routing, ubiquitination, proteasome dependence, glycosylation status, and pathway-specific substrate processing.
Data-Driven Iterative Optimization
We connect construct design, molecular architecture, cellular localization, degradation potency, Dmax, kinetics, and selectivity data to refine ERAD-based degradation systems efficiently.
Clear Reporting and Practical Decision Support
We provide organized experimental results, technical interpretation, and actionable recommendations so clients can confidently decide whether to optimize, redesign, or compare ERAD with another degradation modality.
ERAD-Based Degradation Technology is a targeted protein degradation strategy that utilizes Endoplasmic Reticulum-Associated Degradation (ERAD), a natural protein quality control pathway in the endoplasmic reticulum (ER). Instead of directly recruiting an E3 ligase as in many PROTAC systems, this approach redirects the protein of interest (POI) into ER quality control through glycosylation engineering, ER membrane anchoring, ER retention, chaperone redirecting, or ERAD flux modulation. Once recognized as an ERAD substrate, the target protein can undergo ubiquitination, retrotranslocation, and proteasome-mediated degradation.
What are the structural features of ERAD-Based Degradation Technology?
The structural features of ERAD-Based Degradation Technology depend on the selected degradation strategy. Glyco-ERAD designs often contain engineered N-linked glycosylation motifs or glycosylation-modulating components. ER membrane-anchored or ER-retention degraders may include CAAX boxes, glycosylphosphatidylinositol (GPI) anchoring signals, transmembrane domains, KDEL/HDEL motifs, or KKXX retrieval signals. Chaperone-redirecting degraders usually contain a POI-binding domain and a BiP/Hsp70-engaging domain, while ERAD flux modulators are commonly small molecules that influence deglycosylation or substrate escape.
How does ERAD-Based Degradation differ from PROTACs?
The key difference lies in how the target protein is routed for degradation. PROTACs typically use a bifunctional molecule to bind both the POI and an E3 ubiquitin ligase, inducing proximity-driven ubiquitination. ERAD-Based Degradation instead aims to bring the target into ER quality control and ERAD machinery, where recognition, ubiquitination, retrotranslocation, and degradation are handled by endogenous ERAD-related components such as chaperones, glycoprotein quality control factors, HRD1/gp78-associated ubiquitination systems, and the proteasome.
Which targets are suitable for ERAD-Based Degradation?
ERAD-Based Degradation is especially useful for ER-localized proteins, secretory pathway proteins, membrane-associated targets, engineered glycoproteins, and proteins with ER-accessible or luminal domains. It may also be explored for difficult targets that can be redirected to ERAD through antibody fragments, nanobodies, peptide binders, membrane anchors, ER retention signals, or chaperone-engaging designs. For cytosolic or nuclear proteins, feasibility assessment is important to determine whether effective ERAD routing can be achieved.
How can BOC Sciences support ERAD-Based Degradation projects?
BOC Sciences provides integrated support for ERAD-Based Degradation Technology Development, including target feasibility assessment, N-linked glycosylation site design, ER membrane anchoring and ER-retention construct design, nanobody-anchor peptide conjugate development, BiP/Hsp70 chaperone redirecting strategy design, ERAD flux modulation, ubiquitination analysis, DC50/Dmax degradation profiling, and mechanism-focused validation. By combining protein engineering, chemical biology, and degradation assay expertise, BOC Sciences helps clients design and optimize ERAD-based degradation systems with clearer mechanistic interpretation.
Quick Inquiry
BOC Sciences Support
Please contact us with any specific requirements and we will get back to you as soon as possible.
We invite you to contact us at or through our contact form above for more information about our services and products.
Expands Degradation Beyond Classical PROTAC Design
